Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.36
0.00 (0.00%)
At close: Feb 2, 2026, 4:00 PM EST
7.58
+0.22 (3.04%)
After-hours: Feb 2, 2026, 6:37 PM EST
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $74.38M in the quarter ending September 30, 2025, with 37.06% growth. This brings the company's revenue in the last twelve months to $266.14M, up 42.05% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$266.14M
Revenue Growth
+42.05%
P/S Ratio
4.32
Revenue / Employee
$675,475
Employees
394
Market Cap
1.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AnaptysBio | 169.47M |
| Day One Biopharmaceuticals | 133.67M |
| Immatics | 99.45M |
| Inventiva | 19.93M |
| Capricor Therapeutics | 11.13M |
| Relay Therapeutics | 8.36M |
| Taysha Gene Therapies | 6.31M |
| Compass Therapeutics | 850.00K |
XERS News
- 25 days ago - Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - Business Wire
- 4 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - Business Wire
- 3 months ago - Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - Business Wire
- 3 months ago - Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 4 months ago - Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 months ago - Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy - Seeking Alpha